EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyseOpen Access · CC BY 4.0

Impact of beta blockers on cancer neuroimmunology: a systematic review and meta-analysis of survival outcomes and immune modulation

Fangyuan Zhang, Yu Wang, Feng Liu, Yixian Li, Xinxin Liu, Xueying Ren, Xi Yuan

Frontiers in Immunology · 06.08.2025 · 16

DOI: 10.3389/fimmu.2025.1635331 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Frontiers in Immunology, online erschienen am 06.08.2025. Verfasst von Fangyuan Zhang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Jiangsu Province Hospital of Chinese Medicine, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China. Hauptthemen laut MEDLINE: Adrenergic beta-Antagonists, Neoplasms, Neuroimmunomodulation, Immunomodulation. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 101 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Emerging evidence suggests that beta-blockers (BBs) may influence cancer progression by modulating the neuroimmune axis. However, clinical findings remain heterogeneous, necessitating a comprehensive evaluation of their impact on survival outcomes and immune modulation across malignancies.

Methods

We conducted a systematic review and meta-analysis following PRISMA guidelines, analyzing 79 studies from PubMed, Embase, and Web of Science. Pooled hazard ratios (HRs) for overall survival (OS) and cancer-specific survival (CSS) were calculated using random-effects models. Subgroup analyses explored effects by cancer type, BB class (non-selective vs. β1-selective), and concurrent immunotherapy. Immune biomarkers (e.g., PD-L1 expression, tumor-infiltrating lymphocytes) were qualitatively synthesized.

Results

BB use showed no significant overall effect on CSS (HR = 0.97, 95% CI: 0.92–1.02) but exhibited substantial heterogeneity (I² = 80%). Protective associations were observed in breast cancer (HR = 0.27–0.50) and melanoma, while detrimental effects emerged in pancreatic and head/neck cancers (HR > 1.0). Clinically, BBs combined with immune checkpoint inhibitors (ICIs) improved survival (HR=0.91, 95% CI: 0.85–0.98), particularly in PD-L1+ tumors (OR=1.29 for enhanced expression). Non-selective BBs showed stronger immune modulation (CD8+ T-cell SMD=0.49 vs 0.22 for β1-selective).

Conclusion

BBs demonstrate clinically meaningful benefits when combined with immunotherapy (HR=0.91) particularly in β2-AR+ melanoma and breast cancer, but show potential harm in pancreatic/head-neck cancers (HR>1.0). These results support preferential use of propranolol (20-40mg/day) in immunotherapy-treated melanoma, and avoidance of routine BB use in non-immunogenic tumors without adrenergic profiling. Prospective trials should validate these selection criteria.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Adrenergic beta-AntagonistsNeoplasmsNeuroimmunomodulationImmunomodulationHumansImmunotherapyLymphocytes, Tumor-Infiltrating

Stichwörter der Autor:innen

Beta-blockerscancer neuroimmunologyimmune checkpoint inhibitorsmeta-analysistumor microenvironment

Substanzen

Adrenergic beta-Antagonists

Autor:innen und Institutionen

  • Jiangsu Province Hospital of Chinese Medicine, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China.
  • School of Pharmaceutical Science and Technology, Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences, Hangzhou, China.
  • Department of Oncology, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China.
  • Department of General Surgery, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China.

Zitieren

APA

Zhang, F., Wang, Y., Liu, F., Li, Y., Liu, X., Ren, X., & Yuan, X. (2025). Impact of beta blockers on cancer neuroimmunology: a systematic review and meta-analysis of survival outcomes and immune modulation. Frontiers in Immunology, 16. https://doi.org/10.3389/fimmu.2025.1635331

Vancouver

Zhang F, Wang Y, Liu F, Li Y, Liu X, Ren X, et al. Impact of beta blockers on cancer neuroimmunology: a systematic review and meta-analysis of survival outcomes and immune modulation. Frontiers in Immunology. 2025;16. doi:10.3389/fimmu.2025.1635331

BibTeX
@article{Zhang2025,
  author = {Zhang, Fangyuan and Wang, Yu and Liu, Feng and Li, Yixian and Liu, Xinxin and Ren, Xueying and Yuan, Xi},
  title = {Impact of beta blockers on cancer neuroimmunology: a systematic review and meta-analysis of survival outcomes and immune modulation},
  journal = {Frontiers in Immunology},
  year = {2025},
  volume = {16},
  doi = {10.3389/fimmu.2025.1635331}
}
Kostenlos starten →